- Email: [email protected]
Procedures For Submitting Reviews To The Ocular Surface
MUCOSAL IMMUNITY AND SELF-TOLERANCE / Mircheff, et al 89. Liu SH, Zhou DH, Hess AD. Adoptive transfer of experimental autoimmune dacryoadenitis in susceptible and resistant mice. Cell Immunol 1993;150:311-20 90. Saegusa K, Ishimaru N, Yanagi K, et al. Prevention and induction of autoimmune exocrinopathy is dependent on pathogenic autoantigen cleavage in murine Sjogren’s syndrome. J Immunol 2002;169:1050-7 91. Iltanen S, Collin P, Korpela M, et al. Celiac disease and markers of celiac disease latency in patients with primary Sjogren’s syndrome. Am J Gastroenterol 1999;94:1042-6 92. Li DQ, Chen Z, Song XJ, et al. Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2004;45:4302-11 93. Nagy E, Berczi I, Wren GE, et al. Immunomodulation by bromocriptine. Immunopharmacology 1983;6:231-43 94. Mathers WD, Stovall D, Lane JA, et al. Menopause and tear function: the influence of prolactin and sex hormones on human tear production. Cornea 1998;17:353-8 95. Morales P, Carretero MV, Geronimo H, et al. Influence of prolactin on the differentiation of mouse B-lymphoid precursors. Cell Growth Differ 1999;10:583-90 96. Richards SM, Garman RD, Keyes L, et al. Prolactin is an antagonist of TGF-beta activity and promotes proliferation of murine B cell hybridomas. Cell Immunol 1998;184:85-91 97. Mukherjee P, Mastro AM, Hymer WC. Prolactin induction of interleukin-2 receptors on rat splenic lymphocytes. Endocrinology 1990;126:88-94 98. Viselli SM, Stanek EM, Mukherjee P, et al. Prolactin-induced mitogenesis of lymphocytes from ovariectomized rats. Endocrinology 1991;129:983-90 99. Matera L, Mori M. Cooperation of pituitary hormone prolactin with interleukin-2 and interleukin-12 on production of interferon-g by natural killer and T cells. Ann NY Acad Sci 2000;917:505-13 100. Matera L, Beltramo E, Martinuzzi E, Buttiglieri S. Effect of prolactin on carcinoembryonic antigen-specific cytotoxic
T lymphocyte response induced by dendritic cells. Clin Exp Immunol 1004;320-8 101. Guschchin GV, Cheney C, Glaser R, Malarkey WB. Temporal relationships and IL-2 dependency of prolactin-induced lymphocyte proliferation. J Neuroimmunol 1995;60:93-8 102. Yu-Lee LY. Stimulation of interferon regulatory factor-1 by prolactin. Lupus 2001;10:691-9 103. Pflugfelder SC. Anti-inflammatory therapy of dry eye. Ocular Surface 2003;1:31-6 104. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 2000;107:967-74 105. Stern ME, Pflugfelder SC. Inflammation in dry eye. The Ocular Surface 2004;2:124-30 106. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004;137:337-42 107. Scott G, Yiu SC, Wasilewski D, et al. Combined esterified estrogen and methyltestosterone treatment for dry eye syndrome in postmenopausal women. Am J Ophthalmol 2005;139:1109-10 108. Zhu Z, Stevenson D, Schechter JE, et al. Prophylactic effect of IL-10 gene transfer on induced autoimmune dacryoadenitis. Invest Ophthalmol Vis Sci 2004;45:1375-81 109. Zhu Z, Stevenson D, Schechter JE, et al. Tumor necrosis factor inhibitor gene expression suppresses lacrimal gland immunopathology in a rabbit model of autoimmune dacryoadenitis. Cornea 2003;22:343-51 110. Zhu Z, Stevenson D, Schechter, JE, et al. Expression of TNF inhibitor gene in the lacrimal gland promotes recovery of tear production and tear stability and reduced immunopathology in rabbits with induced autoimmune dacryoadenitis. J Autoimmune Dis, in press (2005) 111. Horwitz DA, Gray JD, Zheng SG. The potential of human regulatory T cells generated ex vivo as a treatment for lupus and other chronic inflammatory diseases. Arthritis Res 2002;4:241-6
PROCEDURES FOR SUBMITTING REVIEWS TO THE OCULAR SURFACE For additional details, see “Information for Authors” at www.theocularsurface.com The purpose of articles in this journal is to help clinicians and researchers stay abreast of developments in the increasingly complex and diverse areas involving the ocular surface. Articles should follow a review format and should be based on representative literature reports. The authors’ own findings may be cited in the context of findings published in the literature, but original work should not be the focus of the review. The purview of The Ocular Surface ranges from molecular biology to surgery, encompassing lacrimal, lid and ocular surface physiology, pathology, pharmacology and medical/surgical therapeutic interventions. Reviews in this journal are usually not general overviews of topics, but, rather, are in-depth, critical reviews that focus on specific areas of the topic. Unsolicited proposals for review articles are welcomed. To propose a review article, please email the following to the Editor-in-Chief, Michael A. Lemp, MD ([email protected].) with a copy to the Managing Editor, Susan Erickson ([email protected]): 1. A narrative statement describing the need for the proposed review and identifying specific controversies, questions, new developments, etc, that you intend to emphasize. 2. A detailed outline of the proposed review. 3. Proprietary interests of the authors in concepts/products discussed in the proposed article must be disclosed. (See www.theocularsurface.com for details.)
As you formulate the outline for your review, bear in mind that the readership of The Ocular Surface is comprised of clinicians, clinical scientists, and laboratory scientists. Readers will have a high level of knowledge in some area(s) related to the ocular surface, but they will not all have detailed knowledge in all areas. Thus, the review should provide in-depth, critical discussion at a level that is understandable and beneficial to basic scientists, as well as more clinically oriented readers. Authors are encouraged to focus on aspects of the topic in which they have special interest, emphasizing particular ideas, controversies, or questions that they feel are exciting and contribute to the understanding of the ocular surface. A review written with this approach will be an original work that reflects the special knowledge and expertise of the authors. Outlines are first reviewed by the editors to determine that they do not overlap substantially with other reviews in development. They then undergo peer review by outside reviewers, who may offer suggestions for revision. All manuscripts are subject to editorial review and revision. Manuscripts will be considered with the understanding that they have not been previously published and are not under consideration for publication in any other journal, book or publicly available electronic source. It may be acceptable to publish portions of the manuscript elsewhere, but this must be approved in advance. Copies of previously published or to-be-considered-for-publication portions of the manuscript should be submitted to Dr. Lemp for evaluation, along with information regarding the other source of dissemination.
THE OCULAR SURFACE / OCTOBER 2005, VOL. 3, NO. 4 / www.theocularsurface.com
193
T lymphocyte response induced by dendritic cells. Clin Exp Immunol 1004;320-8 101. Guschchin GV, Cheney C, Glaser R, Malarkey WB. Temporal relationships and IL-2 dependency of prolactin-induced lymphocyte proliferation. J Neuroimmunol 1995;60:93-8 102. Yu-Lee LY. Stimulation of interferon regulatory factor-1 by prolactin. Lupus 2001;10:691-9 103. Pflugfelder SC. Anti-inflammatory therapy of dry eye. Ocular Surface 2003;1:31-6 104. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study Group. Ophthalmology 2000;107:967-74 105. Stern ME, Pflugfelder SC. Inflammation in dry eye. The Ocular Surface 2004;2:124-30 106. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol 2004;137:337-42 107. Scott G, Yiu SC, Wasilewski D, et al. Combined esterified estrogen and methyltestosterone treatment for dry eye syndrome in postmenopausal women. Am J Ophthalmol 2005;139:1109-10 108. Zhu Z, Stevenson D, Schechter JE, et al. Prophylactic effect of IL-10 gene transfer on induced autoimmune dacryoadenitis. Invest Ophthalmol Vis Sci 2004;45:1375-81 109. Zhu Z, Stevenson D, Schechter JE, et al. Tumor necrosis factor inhibitor gene expression suppresses lacrimal gland immunopathology in a rabbit model of autoimmune dacryoadenitis. Cornea 2003;22:343-51 110. Zhu Z, Stevenson D, Schechter, JE, et al. Expression of TNF inhibitor gene in the lacrimal gland promotes recovery of tear production and tear stability and reduced immunopathology in rabbits with induced autoimmune dacryoadenitis. J Autoimmune Dis, in press (2005) 111. Horwitz DA, Gray JD, Zheng SG. The potential of human regulatory T cells generated ex vivo as a treatment for lupus and other chronic inflammatory diseases. Arthritis Res 2002;4:241-6
PROCEDURES FOR SUBMITTING REVIEWS TO THE OCULAR SURFACE For additional details, see “Information for Authors” at www.theocularsurface.com The purpose of articles in this journal is to help clinicians and researchers stay abreast of developments in the increasingly complex and diverse areas involving the ocular surface. Articles should follow a review format and should be based on representative literature reports. The authors’ own findings may be cited in the context of findings published in the literature, but original work should not be the focus of the review. The purview of The Ocular Surface ranges from molecular biology to surgery, encompassing lacrimal, lid and ocular surface physiology, pathology, pharmacology and medical/surgical therapeutic interventions. Reviews in this journal are usually not general overviews of topics, but, rather, are in-depth, critical reviews that focus on specific areas of the topic. Unsolicited proposals for review articles are welcomed. To propose a review article, please email the following to the Editor-in-Chief, Michael A. Lemp, MD ([email protected].) with a copy to the Managing Editor, Susan Erickson ([email protected]): 1. A narrative statement describing the need for the proposed review and identifying specific controversies, questions, new developments, etc, that you intend to emphasize. 2. A detailed outline of the proposed review. 3. Proprietary interests of the authors in concepts/products discussed in the proposed article must be disclosed. (See www.theocularsurface.com for details.)
As you formulate the outline for your review, bear in mind that the readership of The Ocular Surface is comprised of clinicians, clinical scientists, and laboratory scientists. Readers will have a high level of knowledge in some area(s) related to the ocular surface, but they will not all have detailed knowledge in all areas. Thus, the review should provide in-depth, critical discussion at a level that is understandable and beneficial to basic scientists, as well as more clinically oriented readers. Authors are encouraged to focus on aspects of the topic in which they have special interest, emphasizing particular ideas, controversies, or questions that they feel are exciting and contribute to the understanding of the ocular surface. A review written with this approach will be an original work that reflects the special knowledge and expertise of the authors. Outlines are first reviewed by the editors to determine that they do not overlap substantially with other reviews in development. They then undergo peer review by outside reviewers, who may offer suggestions for revision. All manuscripts are subject to editorial review and revision. Manuscripts will be considered with the understanding that they have not been previously published and are not under consideration for publication in any other journal, book or publicly available electronic source. It may be acceptable to publish portions of the manuscript elsewhere, but this must be approved in advance. Copies of previously published or to-be-considered-for-publication portions of the manuscript should be submitted to Dr. Lemp for evaluation, along with information regarding the other source of dissemination.
THE OCULAR SURFACE / OCTOBER 2005, VOL. 3, NO. 4 / www.theocularsurface.com
193